inVentive Health Logo    Print Page | Close Window

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News

DateTitle
04/19/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective April 19, 2018, the compensation committee of the company’s board of directors granted 9 new employees options to purchase an aggregate of 187,000 shares of the company’s common stock with a per share exercise price of $12.05, the closing trading price on the grant date.  The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commenc... 
04/02/18Coherus BioSciences Management to Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco
REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the H.C. Wainwright Annual Life Sciences Conference on Tuesday, April 10, 2018 at 8:10 am ET being held in Monte Carlo, Monaco. The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com. About Coherus BioSciences, Inc. Coherus is a leading pure-pla... 
03/13/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective March 12, 2018, the compensation committee of the company’s board of directors granted 2 new employees options to purchase an aggregate of 37,000 shares of the company’s common stock with a per share exercise price of $12.45, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencem... 
03/08/18Coherus BioSciences Reports Fourth Quarter and Full Year 2017 Financial Results
REDWOOD CITY, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2017.   Fourth Quarter and Full Year 2017 Financial Results: Research and development (R&D) expenses for the fourth quarter of 2017 were $31.5 million compared to $59.0 million for the same period in 2016.  R&D expenses for the fiscal year 2017 were $162.4 million, as com... 
View All

Upcoming Events

There are currently no events scheduled.
View All

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.